SCHEDULE: Prosight Management Discloses 5.8% Stake in ADC Therapeutics
Beneficial Ownership Report
Prosight Management, LP and affiliated entities have filed an Amendment No. 3 to Schedule 13G, disclosing beneficial ownership of 5.8% of ADC Therapeutics SA's common shares.
Summary
- Prosight Management, LP, Prosight Partners, LLC, and W. Lawrence Hawkins collectively beneficially own 7,195,374 common shares of ADC Therapeutics SA.
- This aggregate ownership represents 5.8% of the Issuer's common shares outstanding.
- Prosight Fund, LP beneficially owns 350,415 common shares, representing 0.3% of the class.
- Prosight Plus Fund, LP beneficially owns 1,586,895 common shares, representing 1.3% of the class.
- The percentage of class is based on 123,877,111 common shares outstanding as of October 31, 2025, as reported in ADC Therapeutics SA's Form 10-Q for the quarter ended September 30, 2025.
- The filing indicates shared voting and dispositive power over the reported shares for the primary reporting persons.
- The securities were not acquired and are not held for the purpose of changing or influencing control of the Issuer.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would inherently convey a positive or negative sentiment regarding the company's performance or prospects. It is a neutral regulatory update.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
NA
Industry Context
This filing is a standard disclosure of beneficial ownership by an institutional investor group, providing transparency into significant holdings in a publicly traded company. It does not provide broader industry trends or competitive analysis.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and trading activity.
Key Dates
| Date | Description |
|---|---|
| 2025-09-30 | Date of event which requires filing of this statement |
| 2025-10-31 | Date as of which 123,877,111 common shares of ADC Therapeutics SA were outstanding |
| 2025-11-10 | Date ADC Therapeutics SA's quarterly report on Form 10-Q for the quarterly period ended September 30, 2025, was filed |
| 2025-11-13 | Date of signing of the Schedule 13G Amendment No. 3 |
Keywords
ADC Therapeutics SA, Prosight Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Shares, H0036K147, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.